Quality Control Testing of Biologics

The Mouse in Biomedical Research

Volumn 3, Issue , 2007, Pages 731-757

  Shek, William R ^a  

^a CHARLES RIVER LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84865819981     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369454-6/50077-7     Document Type: Chapter

References (243)

1. Part 113-Standard requirements, Sec. 113.27- Detection of extraneous viable bacteria and fungi in live vaccines. Code of Federal Regulations, Title 9 2004, Vol 1. 9CFR113.27.
2. Part 211-Current good manufacturing practice for fin- ished Pharmaceuticals, subpart I-laboratory controls, sec. 211.160 General requirements. Code of Federal Regulations, Title 21 2004, Vol 4. 21CFR211.160.
3. Part 610-General biological products standards, sub- part B-general provisions, sec. 610.11 General safety. Code of Federal Regulations, Title 21 2004, Vol 7. 21CFR610.il.
4. Part 610-General biological products standards, sub- part B-general provisions, sec. 610.12 Sterility. Code of Federal Regulations, Title 21 2004, Vol 7. 21CFR610.12.
5. Part 610-General biological products standards, sub- part D-mycoplasma, sec. 610.30 Test for mycoplasma 2004, 21CFR610.30.
6. Akiyoshi D.E., Denaro M., Zhu H., Greenstein J.L., Banerjee P., Fishman J.A. Identification of a full-length cDNA for an endogenous retrovirus of miniature swine. J. Virol 1998, 72:4503-4507.
7. Allen D., Baffi R., Bausch J., Bongers J., Costello M., Dougherty J., et al. Validation of peptide mapping for protein identity and genetic stability: biologies and biotechnology section, pharmaceutical research and manufacturers of America. Biologicals 1996, 24:255-274.
8. Anderson K.P., Low M.A., Lie Y.S., Keller G.A., Dinowitz M. Endogenous origin of defective retroviruslike particles from a recombinant Chinese hamster ovary cell line. Virology 1991, 181:305-311.
9. Andre M., Morgeaux S., Fuchs F. Quantitative detection of RT activ-ity by PERT assay: feasibility and limits to a standardized screening assay for human vaccines. Biologicals 2000, 28:67-80.
10. Andrews N.J., Farrington C.P, Ward H.J., Cousens S.N., Smith P.G., Molesworth A.M., et al. Deaths from variant Creutzfeldt-Jakob disease9 in the UK. Lancet 2003, 361:751-752.
11. Aoki H., Shimazaki T., Takahashi C., Sasaki Y., Suzuki S., Fukusho A. Method for detection of extraneous active bovine viral diarrhoea virus and classical swine fever virus in animal viral vaccines by RT-PCR, which amplify negative-strand viral RNA in infected cells. Biologicals 2002, 30:27-35.
12. Apffel A., Chakel J., Udiavar S., Swedberg S., Hancock W.S., Souders C., Pungor E. Application of new analytical technology to the production of a quot;well-characterized biological. quot;. Dev Biol Stand 1998, 96:11-25.
13. Balls M., Halder M. Progress in applying the three Rs of Russell amp; Burch to the testing of biological products. Dev Biol (Basel) 2002, 111:3-13.
14. Barile M.F. Mycoplasma contamination of cell cultures: incidence, source, prevention and problems of elimination. Tissue culture methods and applications 1973, 729-734. Academic Press, New York. P.F. Kruse, M.K. Patterson (Eds.).
15. Barile M.F., McGarrity G.J. Isolation of mycoplasmas from cell cul- ture by agar and broth techniques. Methods in mycoplasmology volume II. diagnostic mycoplasmology 1983, 159-165. Academic Press, New York. J.G. Tully, S. Razin (Eds.).
16. Baum S.G., Lewis A.M., Rowe W.P., Huebner R.J. Epidemic non-meningitic lymphocytic-choriomeningitis-virus infection: an outbreak in a population of laboratory personnel. N Engl J Med 1966, 274:934-936.
17. Berthold W. Gene stability in mammalian cells and protein consistency. Biologicals 1993, 21:95-100.
18. Besselsen D.G., Wagner A.M., Loganbill J.K. Detection of lympho-cytic choriomeningitis virus by use of fluorogenic nuclease reverse transcriptase-polymerase chain reaction analysis. Comp Med 2003, 53:65-69.
19. Blank W.A., Henderson K.S., White L.A. Virus PCR assay panels: an alternative to the mouse antibody production test. Lab Anim (NY) 2004, 33:26-32.
20. Blazek R., Schmitt K., Krafft U., Hadding U. Fast and simple proce-dure for the detection of cell culture mycoplasmas using a single monoclonal antibody. J Immunol Methods 1990, 131:203-212.
21. Bolin S.R., Ridpath J.F., Black J., Macy M., Roblin R. Survey of cell lines in the American Type Culture Collection for bovine viral diarrhea virus. J. Virol Methods 1994, 48:211-221.
22. Boni J., Stalder J., Reigel F., Schupbach J. Detection of reverse tran-scriptase activity in live attenuated virus vaccines. Clin Diagn Virol 1996, 5:43-53.
23. Bonnard G.D., Manders E.K., Campbell D.A., Herberman R.B., Collins M.J. Immunosuppressive activity of a subline of the mouse EL-4 lymphoma: evidence for minute virus of mice causing the inhibition. JExpMed 1976, 143:187-205.
24. Bootz F., Sieber L, Popovic D., Tischhauser M., Hornberger KR. Comparison of the sensitivity of in vivo antibody production tests with in vitro PCR-based methods to detect infectious contamination of biological materials. Lab Anim 2003, 37:341-351.
25. Brinton M.A. Lactate dehydrogenase-elevating virus. The mouse in biomedical research 1982, 194-208. Academic Press, New York. H.L. Foster, J.D. Small, J. Fox (Eds.).
26. Brinton M.A., Plagemann P.G. Clearance of lactate dehydrogenase by SJL/J mice infected with lactate dehydrogenase-elevating virus. J Reticuloendothel Soc 1983, 33:391-400.
27. Brorson K., De Wit C., Hamilton E., Mustafa M., Swann P.C., Kiss R., et al. Impact of cell culture process changes on endogenous retrovirus expression. Biotechnol Bioeng 2002, 80:257-267.
28. Brorson K., Xu Y., Swann PC., Hamilton E., Mustafa M., de Wit C., et al. Evaluation of a quantitative product-enhanced reverse transcriptase assay to monitor retrovirus in mAb cell-culture. Biologicals 2002, 30:15-26.
29. Brorson K., Krejci S., Lee K., Hamilton E., Stein K., Xu Y Bracketed generic inactivation of rodent retroviruses by low pH treatment for monoclonal antibodies and recombinant proteins. Biotechnol Bioeng 2003, 82:321-329.
30. Brown P., Preece M.A., Will R.G. quot;Friendly fire quot; in medicine: hormones, homografts, and Creutzfeldt-Jakob disease. Lancet 1992, 340:24-27.
31. Bruckner L., Stauber N., Brechtbuhl K., Hofmann M.A. Detection of extraneous agents in vaccines using the polymerase chain reaction of Newcastle disease virus in poultry biologicals. Dev Biol Stand 1996, 86:175-182.
32. Buchanan C.R., Preece M.A., Milner R.D. Mortality, neoplasia, and Creutzfeldt-Jakob disease in patients treated with human pituitary growth hormone in the United Kingdom. BMJ 1991, 302:824-828.
33. Bunn T.O. Testing of veterinary biologies in the United States. Dev Biol Stand 1992, 79:187-192.
34. Cardello-Cummings M., McCormack W.M. Mycoplasmas and ure- aplasmas. Infectious diseases 1998, 1990-1995. Saunders, Philadelphia. S.L. Gorbach, J.C. Bartlett, N.R. Blacklow (Eds.).
35. Cavuslu S., Birinci I., Oncul O., Emekdas C., Erdemoglu A. The com-parison of different recombinant hepatitis-B vaccines. Internet J Infect Dis 2002, 2. http://www.ispub.com/ostia/index.php?xmlFilePath=journals/ijid/vol2n2/va ccine.xml.
36. CDC Appendix A: biological safety cabinets. Biosafety in microbio- logical and biomedical laboratories 1994, 138-145. U.S. Government Printing Office, Washington, D.C.
37. Chasey D., Woods S.B. Detection of immunoperoxidase labelled mycoplasmas in cell culture by light microscopy and electronmicroscopy. J Med Microbiol 1984, 17:23-30.
38. Chesebro B. Biomedicine: a fresh look at BSE. Science 2004, 305:1918-1921.
39. Choo Q.L., Kuo C., Weiner A.J., Overby L.R., Bradley D.W., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244:359-362.
40. Christianson G.G., Koski T.A. A comparison of a disposable mem-brane filtration system with a direct inoculation system for the sterility testing of veterinary biologies. J Biol Stand 1983, 11:83-89.
41. Chudy M., Weeke-Luttmann M., Lower J. Hepatitis B virus poly-merase chain reaction: a possible alternative method to the in vivo assay using chimpanzees. Dev Biol Stand 1996, 86:328.
42. Clark T.B. Spiroplasmas: diversity of arthropod reservoirs and host-parasite relationships. Science 1982, 217:57-59.
43. Cloyd M.W., Hartley J.W., Rowe W.P Cell-surface antigens associ-ated with recombinant mink cell focus-inducing murine leukemia viruses. JExpMed 1979, 149:702-712.
44. Cloyd M.W, Hartley J.W, Rowe W.P Lymphomagenicity of recombinant mink cell focus-inducing murine leukemia viruses. J Exp Med 1980, 151:542-552.
45. Clyde W.A. Mycoplasma species identification based upon growth inhibition by specific antisera. J Immunol 1964, 92:958-965.
46. Coffin J.M. Retorviridae: the viruses and their replication. Fields virology 1996, Vol. 2:1767-1848. Lippincott William amp; Wilkins, Philadelphia. B.N. Fields, D.M. Knipe, P.M. Howley (Eds.).
47. Collins M.J., Parker J.C. Murine virus contaminants of leukemia viruses and transplantable tumors. J Natl Cancer Inst 1972, 49:1139-1143.
48. CPMP/BWP Note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses 1996, Vol. CPMP/BWP/268/95. February 2006, European Agency for the Evaluation of Medicinal Products, EMEA. http://www.emea.eu.int/pdfs/human/bwp/026895en.pdf.
49. Note for guidance on the use of bovine serum in the man- ufacture of human biological medicinal products 2003, Vol. CPMP/BWP/793/02. European Agency for the Evaluation of Medicinal Products, EMEA. CPMP/BWP (Ed.).
50. Crawford L.V. A minute virus of mice. Virology 1966, 29:605-612.
51. Croghan D.L., Matchett A., Koski T.A. Isolation of porcine parvovirus from commercial trypsin. Appl Microbiol 1973, 26:431-433.
52. Crosnier J., Ju die;ngers P., Courouce A.M., Laplanche A., Benhamou E., Degos F., et al. [Efficacy of a French hepatitis B vaccine: results of a multicen-ter clinical trial, using a placebo, with double-blind randomized administration]. Bull Acad Natl Med 1980, 164:764-776.
53. de Souza M., Smith A.L. Comparison of isolation in cell culture with conventional and modified mouse antibody production tests for detection of murine viruses. J Clin Microbiol 1989, 27:185-187.
54. Deo Y, Ghebremariam H., Cloyd M. Detection and characterization of murine ecotropic recombinant virus in myeloma and hybridoma cells. Hybridoma 1994, 13:69-76.
55. Donahue R.E., Kessler S.W., Bodine D., McDonagh K., Dunbar C., Goodman S., et al. Helper virus induced T cell lymphoma in non-human primates after retroviral mediated gene transfer. J Exp Med 1992, 176:1125-1135.
56. ElSaadany S., Giulivi A., Hanna N. Modeling rare and emerging dis-eases for the decision making and policy implementation. Bioprocess International 2004, January:30-36.
57. EMEA European Directorate for the Quality of Medicines: cell sub- strates of the production of vaccines for human use. European pharmacopoeia 2002, 148-149. Council of Europe, Strasbourg.
58. Erickson C.A., Landgraf J.C., Wessman S.J., Koski T.A., Moss L.M. Detection and elimination of adventitious agents in continuous cell lines. Dev Biol Stand 1989, 70:59-66.
59. Espeseth D.A. Licensing veterinary biologies in the United States. Dev Biol Stand 1992, 79:17-25.
60. Espeseth D.A. Present systems and future needs for risk assessment of biologicals in the United States of America: the perspective of the regulator. Rev Sci Tech 1995, 14:81-88.
61. Falbo A. Manufacturing process for antithrombin III concentrate: viral validation studies and effects of column re-use on viral safety. Dev Biol (Basel) 2003, 113:81-88.
62. FDA Guideline on validation of the limulus amebocyte lysate test as an end-product endotoxin test for human and animal parenteral drugs, bio- logical products and medical devices 1987, December, United States Food and Drug Administration. http://www.fda.gov/CBER/gdlns/lab.pdf.
63. FDA Revisions to the general safety test requirements for biological products-FDA. Direct final rule: confirmation in part and withdrawal in part. Fed Regist 1998, 63:41718.
64. FDA History of the FDA. FDA Backgrounder 1999, May. http://www.fda.gov/opacom/back_grounders/miles.html.
65. FDA General requirements for blood, blood components, and blood derivatives: donor notification. Final rule. Fed Regist 2001, 66:31165-31177.
66. FDA/CBER Supplement to the points to consider in the production and testing of new drugs and biologicals produced by recombinant DNA technol-ogy: nucleic acid characterization and genetic stability. Biologicals 1993, 21:81-83.
67. FDA/CBER Points to consider in the characterization of cell lines used to produce biologicals 1993, July, United States Food and Drug Administration. http://www.fda.gov/CBER/gdlns/ptccell.pdf.
68. FDA/CBER Points to consider in the manufacture and testing of mono-colonal antibody products for human use. J Immunotherapy 1997, 30:214-243.
69. FDA/CBER Supplemental guidance on testing for replication-competent retrovirus in retroviral vector-based gene therapy products and during follow-up of patients in clinical trials using retroviral vectors. Hum Gene Ther 1901, 12:315-320.
70. FDA/CBER Guidance for industry: revised preventive measures to reduce the possible risk of transmission of Cruetzfeldt-Jakob disease (CJD) and variant Cruetzfeldt-Jakob disease (vCJD) by blood and blood products 2002, January, United States Food and Drug Administration. http://www.fda.gov/cber/gdlns/cjdvcjd.pdf.
71. FDA/CDER Guidance for industry: investigating out of specification (OOS) test results for pharmaceutical production 1998, September, United States Food and Drug Administration. http://www.fda.gov/cder/guidance/1212dft.pdf.
72. FDA/CDER amp; CVM Guidance for industry: bioanalytical method validation 2001, May, United States Food and Drug Administration. http://www.fda.gov/cder/guidance/4252fnl.pdf.
73. Fischinger P.J., Blevins C.S., Nomura S. Simple, quantitative assay for both xenotropic murine leukemia and ecotropic feline leukemia viruses. J Virol 1974, 14:177-179.
74. Flechsig E., Weissmann C. The role of PrP in health and disease. Curr Mol Med 2004, 4:337-353.
75. Flint S., Enquist L.W., Krug R.M., Racaniello V.R., Skalka A.M. Virus cultivation, detection and genetics. Virology: molecular biology, pathogenesis and control 2000, 25-55. ASM Press, Washington, D.C.
76. Flint S., Enquist L.W., Krug R.M., Racaniello V.R., Skalka A.M. Patterns of infection: a delicate balance. Virology: molecular biology, pathogenesis and control 2000, 519-551. ASM Press, Washington, D.C.
77. Flint S., Enquist L.W, Krug R.M., Racaniello V.R., Skalka A.M. Processing of viral pre-mRNA. Virology: molecular biology, pathogenesis and control 2000, 198-233. ASM Press, Washington, D.C.
78. Fong C.K., Yang-Feng T.L., Lerner-Tung M.B. Re-examination of the McCoy cell line for confirmation of its mouse origin: karyotyping, electron microscopy and reverse transcriptase assay for endogenous retrovirus. Clin Diagn Virol 1994, 2:95-103.
79. Fradkin J.E., Schonberger L.B., Mills J.L., Gunn W.J., Piper J.M., Wysowski D.K., et al. Creutzfeldt-Jakob disease in pituitary growth hormone recipients in the United States. JAMA 1991, 265:880-884.
80. Freshney R.I. Aseptic technique. Culture of animal cells: a manual of basic technique 1994, 51-61. Wiley-Liss, Inc., New York.
81. Fukumi H., Nishikawa F., Kitayama T. A pneumotropic virus from mice causing hemagglutination. Jpn J Med Sci Biol 1954, 7:345-363.
82. Furesz J., Fanok A., Contreras G., Becker B. Tumorigenicity testing of various cell substrates for production of biologicals. Dev Biol Stand 1989, 70:233-243.
83. Gabridge M.G., Lundin D.J., Gladd M.F. Detection and speciation of common cell culture mycoplasmas by an enzyme-linked immunosorbent assay with biotin-avidin amplification and microporous membrane solid phase. In Vitro Cell Dev Biol 1986, 22:491-498.
84. Galibert F., Hamelin J. Assessing genetic stability of a recombinant protein at the nucleic acid level. Biologicals 1993, 21:107-109.
85. Gardner S.N., Kuczmarski T.A., Vitalis E.A., Slezak T.R. Limitations of TaqMan PCR for detecting divergent viral pathogens illustrated by hepa-titis A, B, C., and E viruses and human immunodeficiency virus. J Clin Microbiol 2003, 41:2417-2427.
86. Garnick R.L. Safety aspects in the quality control of recombinant products from mammalian cell culture. J Pharm BiomedAnal 1989, 7:255-266.
87. Garnick R.L., Ross M.J., Baffi R.A. Characterization of proteins from recombinant DNA manufacture. Bioprocess Technol 1991, 13:263-313.
88. Garnick R.L. Experience with viral contamination in cell culture. Dev Biol Stand 1996, 88:49-56.
89. Garnick R.L. Raw materials as a source of contamination in large-scale cell culture. Dev Biol Stand 1998, 93:21-29.
90. Gibbs C.J., Asher D.M., Brown P.W., Fradkin J.E., Gajdusek D.C. Creutzfeldt-Jakob disease infectivity of growth hormone derived from human pituitary glands. AT. Engl J Med 1993, 328:358-359.
91. Gijsbers L., Koel B., Weggeman M., Goudsmit J., Havenga M., Marzio G. Quantification of residual host cell DNA in adenoviral vectors pro-duced on PER.C6 cells. Hum Gene Ther 2005, 16:393-398.
92. GofT S.P. Retorviridae: the viruses and their replication. Fields virology 1996, Vol. 2:1871-1940. Lippincott Williams amp; Wilkins. D.M. Knipe, P.M. Howley (Eds.).
93. Gross L. A filterable agent, recovered from Ak leukemic extracts, causing salivary gland carcinomas in C3H mice. Proc Soc Exp Biol Med 1953, 83:414-421.
94. Hane B., Tu die;mmler M., Jager K., Schleithoff L., Janssen J.W., Drexler H.G. Differences in DNA fingerprints of continuous leukemia-lymphoma cell lines from different sources. Leukemia 1992, 6:1129-1133.
95. Harbour C., Woodhouse G. Viral contamination of monoclonal antibody preparations: potential problems and possible solutions. Cytotechnology 1990, 4:3-12.
96. Hartley J.W., Rowe WP. A new mouse virus apparently related to the adenovirus group. Virology 1960, 11:645-647.
97. Hawkes R.A. General principles underlying laboratory diagnosis of viral infections. Diagnostic procedures for viral, rickettsial and chlamy- dial infections 1979, 3-48. American Public Health Association, Washington, D.C. E.H. Lennette, N.J. Schmidt (Eds.).
98. Hay R.J., Macy M.L., Chen T.R. Mycoplasma infection of cultured cells. Nature 1989, 339:487-488.
99. Hay R.J. Operator-induced contamination in cell culture systems. Dev Biol Stand 1991, 75:193-204.
100. Hayakawa T. Issues related to harmonization of testing requirements for viral safety. Dev Biol Stand 1996, 88:15-18.
101. Hayashi H., Takata M., Iwamaru Y, Ushiki Y, Kimura K.M., Tagawa Y, et al. Effect of tissue deterioration on postmortem BSE diagnosis by immunobiochemical detection of an abnormal isoform of prion protein. J Vet Med Sci 2004, 66:515-520.
102. Hayflick L. History of cell substrates used for human biologicals. Dev Biol Sta die;ndig 1989, 11-26.
103. Hendershot L., Levitt D. Effects of mycoplasma contamination on immunoglobulin biosynthesis by human B lymphoblastoid cell lines. Infect Immun 1985, 49:36-39.
104. Herrmann K., Erdman D.D. Diagnosis by serologie assays. Diagnostic procedures for viral, rickettsial, and chlamydial infections 1995, 121-138. American Public Health Association, Washington, D.C. E.H. Lennette, D.A. Lennette, E.T. Lennette (Eds.).
105. Hill R.E. Regulation of conditionally licensed biologicals in the United States. Dev Biol (Basel) 2004, 111:147-152.
106. Hill R.E., Randall D.C. The United Statest Department of Agriculture regulation of veterinary biological products: the use of prelicensing evalua-tion and postlicensing monitoring to achieve regulatory compliance. Qual Assur 1995, 4:323-328.
107. Hinman A.R., Fraser D.W., Douglas R.G., Bowen G.S., Kraus A.L., Winkler W.G., Rhodes W.W. Outbreak of lymphocytic choriomeningitis virus infections in medical center personnel. Am J Epidemiol 1975, 101:103-110.
108. Hochstein H.D., Seligmann E.B. Limulus lysate testing of biologies requirements for the rabbit pyrogen test. Prog Clin Biol Res 1979, 29:501-506.
109. Hoinowski A.M., Motola S., Davis R.J., McArdle J.M. Investigation of out-of-specification results. Pharm Technol 2002, 40-50. January. http://www.pharmtech.com.
110. Hornberger F.R., Romano T.R, Sciler P., Hansen G.M., Smith A.L. Enzyme-linked immunosorbent assay for detection of antibody to lympho-cytic choriomeningitis virus in mouse sera, with recombinant nucleoprotein as antigen. Lab Anim Sci 1995, 45:493-496.
111. Hopert A., Uphoff C.C., Wirth M., Hauser H., Drexler H.G. Specificity and sensitivity of polymerase chain reaction (PCR) in compari-son with other methods for the detection of mycoplasma contamination in cell lines. J Immunol Methods 1993, 164:91-100.
112. Horaud F. Introductory remarks: viral safety of biologicals. Dev Biol Stand 1991, 75:3-7.
113. Horsfall F.L., Hahn R.G. A latent virus in normal mice capable of producing pneumonia in its natural host. J Exp Med 1940, 85:391-408.
114. House R.V. Cytokine bioassays: an overview. Dev Biol Stand 1999, 97:13-19.
115. Hughes J.V., Messner K., Burnham M., Patel D., White E.M. Validation of retroviral detection for rodent cell-derived products and gene therapy applications. Dev Biol Stand 1996, 88:297-304.
116. ICH International Conference on Harmonisation. Guidance on quality of biotechnological/biological products: derivation and characterization of cell substrates used for production of biotechnological/biological products: availability. FedRegist 1998, Vol. 63:50244-50249. FDA (Ed.).
117. ICH International Conference on Harmonisation. Guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin; availability-FDA. Notice. FedRegist 1998, 63:51074-51084.
118. ICH International Conference on Harmonisation. Guidance on specifica- tions: test procedures and acceptance criteria for biotechnological/biological products. Notice. Food and Drug Administration, HHS. Fed Regist 1999, 64:44928-44935.
119. ICH History and future of ICH. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use 2005, http://www.ich.org/cache/compo/276-254-1.html.
120. Jacobs J.P., Magrath D.I., Garrett A.J., Schild G.C. Guidelines for the acceptability, management and testing of serially propagated human diploid cells for the production of live virus vaccines for use in man. J Biol Stand 1981, 9:331-342.
121. Jakway J.P., Shevach E.M. Mycoplasma contamination: a hazard of screening hybridoma supernatants for inhibition of [3H]thymidine incorpo-ration. J Immunol Methods 1984, 67:337-345.
122. Jones C. Applications of nuclear magnetic resonance, circular dichro-ism and fluorescence spectroscopy to the characterization of biological products. Biologicals 1993, 21:119-124.
123. Kafatos F.C., Jones C.W., Efstratiadis A. Determination of nucleic acid sequence homologies and relative concentrations by a dot hybridization procedure. Nucleic Acids Res 1979, 7:1541-1552.
124. Karst S.M., Wobus C.E., Lay M., Davidson J., Virgin H.W.T. STAT1-dependent innate immunity to a Norwalk-like virus. Science 2003, 299:1575-1578.
125. Katayama T., Kikuchi S., Tanaka Y., Saito I., Miyamura T., Choo Q.L., et al. Blood screening for non-A, non-B hepatitis by hepatitis C virus antibody assay. Transfusion 1990, 30:374-376.
126. Kendall L.V., Riley L.K. The polymerase chain reaction (PCR). Contemp Top Lab Anim Sci 1999, 38:50.
127. Kendall L.V., Riley L.K. Reverse transcriptase polymerase chain reaction (RT-PCR). Contemp Top Lab Anim Sci 2000, 39:42.
128. Khan A.S., Muller J., Sears J.F. Early detection of endogenous retro-viruses in chemically induced mouse cells. Virus Res 2001, 79:39-45.
129. Kilham L. Isolation in suckling mice of a virus from C3H mice harbor-ing Bittner milk agent. Science 1952, 116:391-392.
130. Kilham L., Olivier L.J. A latent virus of rats isolated in tissue culture. Virology 1959, 7:428-437.
131. Klement V, Rowe W.P., Hartley J.W., Pugh W.E. Mixed culture cytopathogenicity: a new test for growth of murine leukemia viruses in tissue culture. Proc Natl Acad Sci U S A 1969, 63:753-758.
132. Koff R.S. Hepatitis C. Infectious diseases 1998, 864-871. Saunders, Philadelphia. S.L. Gorbach, J.G. Bartlett, N.R. Blacklow (Eds.).
133. Lander M.R., Chattopadhyay S.K. A Mus dunni cell line that lacks sequences closely related to endogenous murine leukemia viruses and can be infected by ectropic, amphotropic, xenotropic, and mink cell focus-forming viruses. J. Virol 1984, 52:695-698.
134. Lehmann-Grube F. Lymphocytic choriomeningitis virus. The mouse in biomedical research 1982, 231-266. Academic Press, New York. H.L. Foster, J.D. Small, J. Fox (Eds.).
135. Lennette D.A. General principles for laboratory diagnosis of viral, rick- ettsial, and chlamydial infections. Diagnostic procedures for viral, rickettsial, and chlamydial infections 1995, 3-26. American Public Health Association, Washington, D.C. E.H. Lennette, D.A. Lennette, E.T. Lennette (Eds.).
136. Levin J., Bang F.B. Clottable protein in Limulus: its localization and kinetics of its coagulation by endotoxin. Thromb Diath Haemorrh 1968, 19:186-197.
137. Lewis A.M., Rowe W.P., Turner H.C., Huebner R.J. Lymphocytic-choriomeningitis virus in hamster tumor: spread to hamsters and humans. Science 1965, 150:363-364.
138. Li K.S., Guan Y, Wang J., Smith G.J., Xu K.M., Duan L., et al. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 2004, 430:209-213.
139. Lim G., Karaskova J., Vukovic B., Bayani J., Beheshti B., Bernardini M., et al. Combined spectral karyotyping, multicolor banding, and microarray comparative genomic hybridization analysis provides a detailed characterization of complex structural chromosomal rearrangements associ-ated with gene amplification in the osteosarcoma cell line MG-63. Cancer Genet Cytogenet 2004, 153:158-164.
140. Lincoln C.K., Gabridge M.G. Cell culture contamination: sources, consequences, prevention, and elimination. Methods Cell Biol 1998, 57:49-65.
141. Lipman N.S., Perkins S., Nguyen H., Pfeffer M., Meyer H. Mousepox resulting from use of ectromelia virus-contaminated, imported mouse serum. Comp Med 2000, 50:426-435.
142. Lloyd G., Jones N. Infection of laboratory workers with hantavirus acquired from immunocytomas propagated in laboratory rats. J Infect 1986, 12:117-125.
143. Lovatt A., Black J., Galbraith D., Doherty I., Moran M.W., Shepherd A.J., et al. High throughput detection of retrovirus-associated reverse tran-scriptase using an improved fluorescent product enhanced reverse transcriptase assay and its comparison to conventional detection methods. J Virol Methods 1999, 82:185-200.
144. Lubiniecki A.S., May L.H. Cell bank characterization for recombinant DNA mammalian cell lines. Dev Biol Stand 1985, 60:141-146.
145. Lubiniecki A.S., Dinowitz M., Nelson E., Wiebe M., May L., Ogez J., Builder S. Endogenous retroviruses of continuous cell substrates. Dev Biol Stand 1989, 70:187-191.
146. Lugert R., Ko die;nig H., Kurth R., Tonjes R.R. Specific suppression of false-positive signals in the product-enhanced reverse transcriptase assay. Biotechniques 1996, 20:210-217.
147. Lute S., Aranha H., Tremblay D., Liang D., Ackermann H.W., Chu B., et al. Characterization of coliphage PR772 and evaluation of its use for virus filter performance testing. Appl Environ Microbiol 2004, 70:4864-4871.
148. Malmsten A. Reverse transcriptase activity assays for retrovirus quan- titation and characterization. Department of genetics and pathology 2005, Vol. Ph.D., Uppsala University, Uppsala.
149. Mannucci P.M., Colombo M. Virucidal treatment of clotting factor concentrates. Lancet 1988, 2:782-785.
150. Maudru T., Peden K.W. Actaptation of the fluorogenic 5'-nuclease chemistry to a PCR-based reverse transcriptase assay. Biotechniques 1998, 25:972-975.
151. McGarrity G.J., Carson D.A. Adenosine phosphorylase-mediated nucle-oside toxicity: application towards the detection of mycoplasmal infection in mammalian cell cultures. Exp Cell Res 1982, 139:199-205.
152. McGarrity G.J., Barile M.F. Use of indicator cell lines for recovery and identification of cell culture mycoplasmas. Methods in mycoplasmology. Volume II. diagnostic mycoplasmology 1983, 167-172. Academic Press, New York. J.G. Tully, S. Razin (Eds.).
153. McGarrity G.J., Lindsay G., Sarama J. Prevention and control of mycoplasma infection. Methods in mycoplasmology. Volume II. diagnostic mycoplasmology 1983, 203-208. Academic Press, New York. J.G. Tully, S. Razin (Eds.).
154. McGarrity G.J., Vanaman V., Sarama J. Cytogenetic effects of mycoplasmal infection of cell cultures: a review. In Vitro 1984, 20:1-18.
155. McKisic M.D., Lancki D.W., Otto G., Padrid P., Snook S., Cronin D.C., et al. Identification and propagation of a putative immunosup-pressive orphan parvovirus in cloned T cells. J Immunol 1993, 150:419.
156. Melnick J.L. Virus inactivation: lessons from the past. Dev Biol Stand 1991, 75:29-36.
157. Miller S.E. Diagnosis of viral infections by electron microscopy. Diagnostic procedures for viral, rickettsial, and chlamydial infections 1995, 37-78. American Public Health Association, Washington, D.C. E.H. Lennette, D.A. Lennette, E.T. Lennette (Eds.).
158. Mire-Sluis A.R. Analytical characterisation of cytokines and growth factors. Dev Biol Stand 1999, 97:3-9.
159. Mire-Sluis A.R., Gerrard T., Das R.G., Padilla A., Thorpe R. Biological assays: their role in the development and quality control of recombinant biological medicinal products. Biologicals 1996, 24:351-362.
160. Moore W.A. Experience in cell line testing. Dev Biol Stand 1992, 76:51-56.
161. Mortimer E.A., Lepow M.L., Gold E., Robbins EC., Burton G.J., Fraumeni J.F. Long-term follow-up of persons inadvertently inoculated with SV40 as neonates. N EnglJ Med 1981, 305:1517-1518.
162. Mosesson M.W., Wolfenstein-Todel C., Levin J., Bertrand O. Characterization of amebocyte coagulogen from the horseshoe crab (Limulus polyhemus). Thromb Res 1979, 14:765-779.
163. Myers C., Frisque R.J., Arthur R.R. Direct isolation and characteriza-tion of JC virus from urine samples of renal and bone marrow transplant patients. J Virol 1989, 63:4445-4449.
164. Nathanson N., Langmuir A.D. The Cutter incident: poliomyelitis fol-lowing formaldehyde-inactivated poliovirus vaccination in the United States during the spring of 1955.1. Background. AmJHyg 1963, 78:16-28.
165. Nettleton P.F., Rweyemamu M.M. The association of calf serum with the contamination of BHK21 clone 13 suspension cells by a parvovirus sero-logically related to the minute virus of mice (MVM). Arch Virol 1980, 64:359-374.
166. Nexo B.A. A plaque assay for murine leukemia virus using enzyme-coupled antibodies. Virology 1977, 77:849-852.
167. Nicklas W., Giese M., Zawatzky R., Kirchner H., Eaton P. Contamination of a monoclonal antibody with LDH-virus causes interferon induction. Lab Anim Sci 1988, 38:152-154.
168. Nicklas W., Kraft V., Meyer B. Contamination of transplantable tumors, cell lines, and monoclonal antibodies with rodent viruses. Lab Anim Sci 1993, 43:296-300.
169. Nims R.W., Shoemaker A.P., Bauernschub M.A., Rec L.J., Harbell J.W. Sensitivity of isoenzyme analysis for the detection of interspecies cell line cross-contamination. In Vitro Cell Dev Biol Anim 1998, 34:35-39.
170. Onions D., Lees G. Human retroviruses and herpes viruses: problems and solutions in safety testing of biologicals. Dev Biol Stand 1991, 75:145-158.
171. Oram J.D., Crooks A.J. A comparison of labelled antibody methods for the detection of virus antigens in cell monolayers. J Immunol Methods 1979, 25:297-310.
172. Para M. An outbreak of post-vaccinal rabies (rage de laboratoire) in Fortaleza, Brazil, in 1960: residual fixed virus as the etiological agent. Bull World Health Organ 1965, 33:177-182.
173. Patience C., Takeuchi Y., Weiss R.A. Infection of human cells by an endogenous retrovirus of pigs. Nat Med 1997, 3:282-286.
174. Peebles P.T., Fischinger P.J., Bassin R.H., Papageorge A.G. Isolation of human amnion cells transformed by rescuable murine sarcoma virus. Nat New Biol 1973, 242:98-101.
175. Peebles P.T. An in vitro focus-induction assay for xenotropic murine leukemia virus, feline leukemia virus C., and the feline: primate viruses RD-114/CCC/M-7. Virology 1975, 67:288-291.
176. Petricciani J.C. Regulatory philosophy and acceptability of cells for the production of biologicals. Dev Biol Stand 1991, 75:9-15.
177. Petricciani J.C., Horaud F.N. Karyology and tumorigenicity testing requirements: past, present and future. Dev Biol Stand 1998, 93:5-13.
178. Poiley J.A. Methods for the detection of adventitious viruses in cell cultures used in the production of biotechnology products. Bioprocess Technol 1990, 10:483-494.
179. Polak-Vogelzang A.A., Brugman J., Reijgers R. Comparison of two methods for detection of mollicutes (Mycoplasmatales and Acholeplasmatales) in cell cultures in the Netherlands. Antonie Van Leeuwenhoek 1987, 53:107-118.
180. Prusiner S.B. Prions. Fields virology 1996, Vol. 2:2901-2944. Lippincott Williams amp; Wilkins, Philadelphia. B.N. Fields, D.M. Knipe, P.M. Howley (Eds.).
181. Rabenau H., Ohlinger V., Anderson J., Selb B., Cinatl J., Wolf W, et al. Contamination of genetically engineered CHO-cells by epizootic haemorrhagic disease virus (EHDV). Biologicals 1993, 21:207-214.
182. Randall D.C. Inspection of veterinary biologies in the United States. Dev Biol Stand 1992, 79:163-170.
183. Rascati R.J. Effects of cytidine analogs on methylation of DNA and retrovirus induction. Mutat Res 1988, 208:21-25.
184. Razin S. DNA probes and PCR in diagnosis of mycoplasma infections. Mol Cell Probes 1994, 8:497-511.
185. Razin S. Mycoplasmas. Medical microbiology 1996, 475-4485. The University of Texas Medical Branch at Galveston, Galveston. S. Baron (Ed.).
186. Razin S., Gross M., Wormser M., Pollack Y., Glaser G. Detection of mycoplasmas infecting cell cultures by DNA hybridization. In Vitro 1984, 21:404-408.
187. Reeves L., Duffy L., Koop S., Fyffe J., Cornetta K. Detection of ecotropic replication-competent retroviruses: comparison of s (+) /l (-) and marker rescue assays. Hum Gene Ther 2002, 13:1783-1790.
188. Riggs J.L., McAllister R.M., Lennette E.H. Immunofluorescent studies of RD-114 virus replication in cell culture. J Gen Virol 1974, 25:21-29.
189. Riley V., Lilly F., Huerto E., Bardell D. Transmissible agent associ-ated with 26 types of experimental mouse neoplasms. Science 1960, 132:545-547.
190. Robertson J.S. Strategy for adventitious agent assays. Dev Biol Stand 1996, 88:37-40.
191. Robertson J.S. Viruses and assuring viral safety. Dev Biol (Basel) 2003, 113:73-77.
192. Robinson C.J. Bioassays for growth factors. Dev Biol Stand 1999, 97:21-27.
193. Roizman B. Multiplication. Medical microbiology 1996, 543-554. The University of Texas Medical Branch at Galveston, Galveston. B. S. (Ed.).
194. Roth R.I., Levin J. Purification of Limulus polyphemus proclotting enzyme. J Biol Chem 1992, 267:24097-24102.
195. Rowe W.P., Hartley J.W, Estes J.D., Huebner R.J. Studies of mouse polyoma virus infection. I. Procedures for quantitation and detection of virus. J. Exp Med 1959, 109:379-391.
196. Rowe W.P., Capps W.I. A new mouse virus causing necrosis of the thymus in newborn mice. J. Exp Med 1961, 113:831-844.
197. Rowe W.P., Hartley J.W, Huebner R.J. Polyoma and other indigenous mouse viruses. The problems of laboratory animal disease 1962, 131-142. Academic Press, New York. R.J.C. Harris (Ed.).
198. Rowe W.P., Cloyd M.W, Hartley J.W Status of the association of mink cell focus-forming viruses with leukemogenesis. Cold Spring Harb Symp Quant Biol 1980, 44 (Pt 2:1265-1268.
199. Schmidt N.J. Cell culture techniques for diagnostic virology. Diagnostic procedures for viral, rickettsial and chlamydial infections 1979, 65-139. American Public Health Association, Washington, D.C. E.H. Lennette, N.J. Schmidt (Eds.).
200. Schuurman R., van Steenis B., Sol C Bovine polyomavirus, a frequent contaminant of calf serum. Biologicals 1991, 19:265-270.
201. Shah K., Nathanson N. Human exposure to SV40: review and comment. Am J Epidemiol 1976, 103:1-12.
202. Shah K.V., Rollison D.E. Investigation of the SV40-human cancer association: look for the full signature of the virus. Dis Markers 2001, 17:159-161.
203. Shek WR. Detection of murine viruses in biological materials by the mouse antibody production test 1983, Marcel Dekker, Inc., New York.
204. Shek W.R., Gaertner D.J. Microbiological quality control for rodents and lagomorphs. Lab animal medicine 2002, 365-393. Academic Press, New York. 2nd ed. J. Fox, L. Anderson, M. Loew, E. Quimby (Eds.).
205. Shepherd A.J., Wilson N.J., Smith K.T. Characterisation of endoge-nous retrovirus in rodent cell lines used for production of biologicals. Biologicals 2003, 31:251-260.
206. Silver J., Maudru T., Fujita K., Repaske R. An RT-PCR assay for the enzyme activity of reverse transcriptase capable of detecting single virions. Nucleic Acids Res 1993, 21:3593-3594.
207. Smith A.L. Serologie tests for detection of antibody to rodent viruses. Viral and mycoplasmal infections of laboratory rodents: effects on bio- medical research 1986, 731-749. Academic Press, Orlando. P.N. Bhatt, R.O. Jacoby, S.S. Morse, A. New (Eds.).
208. Spiropoulou C.F., Morzunov S., Feldmann H., Sanchez A., Peters C.J., Nichol S.T. Genome structure and variability of a virus causing hantavirus pulmonary syndrome. Virology 1994, 200:715-723.
209. Stacey A., Doyle A. Routine testing of cell cultures and their products for mycoplasma contamination. Methods Mol Biol 1997, 75:305-311.
210. Stacey G., Bolton B., Doyle A., Griffiths B. DNA fingerprinting: a valuable new technique for the characterisation of cell lines. Cytotechnology 1992, 9:211-216.
211. Swann J.P. History of the FDA 1998, http://www.fda.gov/oc/history/historyoffda/default.htm.
212. Takeuchi Y., Patience C., Magre S., Weiss R.A., Banerjee P.T., Le Tissier P., Stoye J.P. Host range and interference studies of three classes of pig endogenous retrovirus. J Virol 1998, 72:9986-9991.
213. Tenover F.C. Molecular techniques for the detection and identification of infectious agents. Infectious diseases 1998, 152-156. Saunders, Philadelphia. S.L. Gorbach, J.G. Bartlett, N.R. Blacklow (Eds.).
214. Theiler M. Spontaneous encephalomyelitis of mice: a new virus disease. Science 1937, 65:705-719.
215. Thornton D.H. A survey of mycoplasma detection in veterinary vaccines. Vaccine 1986, 4:237-240.
216. Thornton D.H., Maley A.D., Frerichs G.N. Sterility testing of immuno-logical products: comparative efficacy of media and effect of preservatives. J Biol Stand 1987, 15:117-126.
217. Thuring C.M., van Keulen L.J., Langeveld J.P., Vromans M.E., van Zijderveld F.G., Sweeney T. Immunohistochemical distinction between preclinical bovine spongiform encephalopathy and scrapie infection in sheep. J Comp Pathol 2005, 132:59-69.
218. Tolbert W.R., Rupp R.G. Manufacture of pharmaceutical proteins from hybridomas and other cell substrates. Dev Biol Stand 1989, 70:49-56.
219. Trachtenberg S. Shaping and moving a spiroplasma. J Mol Microbiol Biotechnol 2004, 7:78-87.
220. Trescec A., Valinger Z., Smerdel S., Tomasic J. Determination of foetal calf serum in vaccine preparations by immunoradiometric assay and enzyme-linked immunosorbent assay. Biologicals 1993, 21:163-168.
221. Uchida E., Sato K., Iwata A., Ishii-Watabe A., Mizuguchi H., Hikata M., et al. An improved method for detection of replication-competent retrovirus in retrovirus vector products. Biologicals 2004, 32:139-146.
222. Uphoff C.C., Drexler H.G. Comparative PCR analysis for detection of mycoplasma infections in continuous cell lines. In Vitro Cell Dev Biol Anim 2002, 38:79-85.
223. Uphoff C.C., Drexler H.G. Detecting mycoplasma contamination in cell cultures by polymerase chain reaction. Methods Mol Med 2004, 88:319-326.
224. Uphoff C.C., Gignac S.M., Drexler H.G. Mycoplasma contamination in human leukemia cell lines. I. Comparison of various detection methods. /. Immunol Methods 1992, 149:43-53.
225. USDHHS/PHS/NTP Report on carcinogens 2005, U.S. Department of Health and Human Services, Public Health Service, National Toxicology Program. http://www.ntp-server.niehs.nih.gov/ntp/roc/toc11.html, 11th ed.
226. USP Pyrogen test 151. USP 24 2000, 1850. The United States Pharamcopeial Convention, Rockville.
227. USP Sterility Tests 71. USP 24 2000, 1818-1823. The United States Pharamcopeial Convention, Rockville.
228. USP Microbial limit tests 61. USP 24 2000, 1814-1818. The United States Pharamcopeial Convention, Rockville.
229. van Kuppeveld F.J., Johansson K.E., Galama J.M., Kissing J., Bolske G., van der Logt J.T., Melchers W.J. Detection of mycoplasma contam-ination in cell cultures by a mycoplasma group-specific PC.R. Appl Environ Microbiol 1994, 60:149-152.
230. VICH Validation of analytical procedures: methodology. International Cooperation on Harmonization of Technical Requirements for Registration of Veterinary Medicinal Products 1998, October. VICH GL1., VICH. http://www.fda.gov/cvm/Guidance/guida64.pdf.
231. VICH Validation of analytical procedures: definition and terminology. International Cooperation on Harmonization of Technical Requirements for Registration of Veterinary Medicinal Products 1998, VICH, tober. VICH GL1. http://www.fda.gov/cvm/Guidance/guida63.pdf.
232. VICH Testing for the detection of mycoplasma contamination 2002, Vol. VICH GL34, VICH.
233. VICH Target animal safety: examination of live veterinary vaccines in target animals for absence of reversion to virulence. International Cooperation on Harmonization of Technical Requirements for Registration of Veterinary Medicinal Products 2004, 41. April, VICH GL. http://www.emea.eu.int/pdfs/vet/vich/046302en.pdf.
234. Wiebe M.E., May L.H. Cell banking. Bioprocess Technol 1990, 10:147-160.
235. Will R.G., Ironside J.W., Zeidler M., Cousens S.N., Estibeiro K., Alperovitch A., et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996, 347:921-925.
236. Wilson G.S. The hazards of immunization 1967, The Athlone Press, London.
237. Winkler D., Lukaszewicz V. Long-term analysis of sterility testing of immunobiological preparations. J Hyg Epidemiol Microbiol Immunol 1989, 33:317-322.
238. Wisher M. Biosafety and product release testing issues relevant to replication-competent oncolytic viruses. Cancer Gene Ther 2002, 9:1056-1061.
239. Woodward R.S. Ethical considerations in the testing of biopharmaceu-ticals for adventitious agents. Sci Eng Ethics 1995, 1:273-282.
240. Xu Y., Brorson K. An overview of quantitative PCR assays for biologicals: quality and safety evaluation. Dev Biol (Basel) 2003, 113:89-98.
241. Zhan D., Roy M.R., Valera C., Cardenas J., Vennari J.C., Chen J.W., Liu S. Detection of minute virus of mice using real time quantitative PCR in assessment of virus clearance during the purification of mammalian cell substrate derived biotherapeutics. Biologicals 2002, 30:259-270.
242. Zhang D.L., Ji L., Li L.J., Huang G.S. Systematically experimental investigation on carcinogenesis or tumorigenicity of VERO cell lines of dif-ferent karyotypes in nude mice in vivo used for viral vaccine manufacture. Yi Chuan Xue Bao 2004, 31:647-660.
243. Zhang P.F., Klutch M., Muller J., Marcus-Sekura C.J. Susceptibility of the Sf9 insect cell line to infection with adventitious viruses. Biologicals 1994, 22:205-213.